Chimeric antigen receptor T-cell (CART) therapy: current data, future potential

An article in today’s issue of the New England Journal of Medicine reports data from a Phase II trial of CART therapy in the treatment of patients with acute lymphoblastic leukemia or ALL (an aggressive and difficult to treat form of cancer). This is arguably one of the most exciting papers on the treatment of cancer in the past 50+ years. … READ MORE …

Will CART-type treatments be usable to treat prostate cancer?

Many of our readers may be aware of what is known as “chimeric antigen receptor T-cell” therapy (often known as CART), and its development by Carl June and colleagues at the University of Pennsylvania over the past few years. … READ MORE …